NfL may aid in monitoring disease severity and progression in SPMS (secondary progressive multiple sclerosis). Simvastatin's neuroprotective effects warrant further validation in phase 3 trials. The gene discussed is NEFL; the disease is secondary progressive multiple sclerosis.